Genentech, a member of the Roche Group OTC: RHHBY),
today announced that the U.S. Food and Drug Administration (FDA) has
accepted the company's Biologics License Application (BLA) for
…
Genentech, a member of the Roche Group OTC: RHHBY),
today announced that the U.S. Food and Drug Administration (FDA) has
accepted the company's Biologics License Application (BLA) for
obinutuzumab (GA101) and granted Priority Review for GA101 in the
treatment of chronic lymphocytic leukemia (CLL), one of the most common
forms of blood cancer, based on final Stage 1 data from the pivotal
CLL11 trial. The FDA confirmed the action date is December 20, 2013.
This acceptance follows the GA101 FDA Breakthrough Therapy Designation
that was received in May 2013.
“We're excited that the FDA has granted GA101 in CLL both Breakthrough
Therapy Designation and Priority Review,” said Hal Barron, M.D., chief
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in